Short answer
Mirum Pharmaceuticals, Inc. (MIRM) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results and corporate update announced for quarter ended June 30, 2026.
Mirum Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results and corporate update announced for quarter ended June 30, 2026
- Full results and management commentary available in Exhibit 99.1
- Disclosure furnished under Regulation FD, generally not subject to Exchange Act Section 18 liability
Item EX-99.1 · Exhibit EX-99.1
- Q2 net product sales $176.2M, up from $127.8M, led by LIVMARLI sales $128.7M, up 46% year over year
- 2026 sales guidance raised to $680M-$700M, signaling stronger commercial momentum and increased revenue visibility
- Volixibat PSC NDA target shifted to H1 2027 after FDA recommended a Phase 3 study, extending development timeline and potential launch
- Zilurgisertib FOP NDA under Priority Review, with FDA action date September 26, 2026, creating a near-term regulatory catalyst
- Cash, equivalents, and investments $561.3M, while Q2 net loss widened to $67.2M amid $218.8M operating expenses and pipeline investment
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Mirum Pharmaceuticals, Inc. 8-K filings
Get the next MIRM 8-K as it lands
Follow MIRM for push alerts, or ask the research agent what this filing means.